Arabic Arabic English English French French German German
dark

Oridonin inhibits LPS-induced inflammation in human gingival fibroblasts by activating PPARγ.

PMID: 

Int Immunopharmacol. 2019 Jul ;72:301-307. Epub 2019 Apr 18. PMID: 31005040

Abstract Title: 

Oridonin inhibits LPS-induced inflammation in human gingival fibroblasts by activating PPARγ.

Abstract: 

Oridonin, the major terpene isolated from Rabdosia rubescens, has been used as dietary supplement. Recently, it has been known to exhibit anti-inflammatory effect. This study we employed an in vitro model of LPS-stimulated human gingival fibroblasts to investigate the anti-inflammatory effects and mechanism of oridonin. Oridonin (10-30 μg/mL) was administrated 1 h before LPS treatment. The results showed that oridonin significantly inhibited inflammatory mediators PGE, NO, IL-6, and IL-8 production. Immunoblotting experiments revealed that oridonin reduced the expression of phosphorylation levels of NF-κB p65 and IκBα. Furthermore, the expression of PPARγ was up-regulated by the treatment of oridonin. Further studies showed that PPARγ inhibitor GW9662 could reverse the inhibition of oridonin on PGE, NO, IL-6, and IL-8 production. In conclusion, oridonin inhibited LPS-induced microglia activation through activating PPARγ.

read more

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Oridonin protects against cardiac hypertrophy by promoting P21-related autophagy.

Next Post

Oridonin might be an effective drug for the prevention and treatment of lipopolysaccharide-induced endometritis.

Related Posts
Total
0
Share